InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) saw a significant decrease in short interest in May. As of May 15th, there was short interest totaling 2,773,329 shares, a decrease of 50.9% from the April 30th total of 5,643,832 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.
InnoCare Pharma Stock Performance
INCPF remained flat at $1.55 during trading on Wednesday. The stock’s fifty day moving average is $1.55 and its 200-day moving average is $1.83. InnoCare Pharma has a twelve month low of $1.55 and a twelve month high of $2.31.
Analyst Ratings Changes
Separately, Morgan Stanley upgraded InnoCare Pharma to an “overweight” rating in a report on Thursday, May 28th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy”.
About InnoCare Pharma
InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.
The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.
Further Reading
- Five stocks we like better than InnoCare Pharma
- What IBM’s $10-Billion Quantum Project Means For Smaller Players
- HIVE Earnings Highlight AI Ambitions Beyond Bitcoin Mining
- Microsoft Build 2026 Is Really Just One Big AI Stress Test
- Slice of the Pie: Why Yum’s Deal Lifts QSR
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
